ORIC Expects $345.4 Million To Fund Cancer Trials Beyond Its First Late-Stage Readout

Research spending rose to $43.4 million as the prostate-cancer program advanced, while a late-stage lung-cancer trial is planned for 2027.

Share
ORIC Expects $345.4 Million To Fund Cancer Trials Beyond Its First Late-Stage Readout

ORIC Pharmaceuticals, which is testing drugs for prostate and lung cancer, expects its $345.4 million in cash and investments to last beyond the anticipated main results of its first late-stage rinzimetostat trial. The company reported the September 30 balance in its earnings release attached to Monday's SEC filing, projecting funding into the second half of 2028.

More Spending On Rinzimetostat

ORIC's third-quarter research spending climbed to $43.4 million from $28.8 million a year earlier. The company attributed the increase mainly to advancing rinzimetostat, partly offset by lower enozertinib spending because of manufacturing and clinical-cost timing.

The unaudited quarterly net loss widened to $48.1 million, or $0.44 per share, from $32.6 million, or $0.33 per share. Administrative costs rose to $8.2 million from $7.9 million, primarily because of higher professional-services costs.

For the first nine months, research spending reached $111.1 million versus $84.0 million a year earlier, while net loss increased to $125.3 million from $99.0 million. The cash balance includes $59.9 million in net proceeds from first-quarter stock sales to healthcare specialist funds.

ORIC has no approved products. Its development work targets treatment resistance—the ability of tumors to stop responding to cancer medicines.

A 600-Patient Prostate-Cancer Test

ORIC has started Himalayas-1, a global late-stage trial of rinzimetostat combined with darolutamide for advanced prostate cancer previously treated with abiraterone. It expects to enroll approximately 600 patients across more than 250 sites in 25 countries.

Patients will receive either the combination or a physician-selected androgen-receptor inhibitor or docetaxel. The main goal is to measure survival without cancer worsening on scans; overall survival is a key secondary measure. Bayer will supply darolutamide free, while ORIC sponsors the trial and keeps worldwide rights to rinzimetostat.

Updated early-stage combination data estimated that 59% of patients in each of two cohorts were alive without scan-detected progression at 10 months. One cohort included 18 patients previously treated with abiraterone; the other included 19 previously treated with an androgen-receptor inhibitor. The estimates remain preliminary, with 28% and 32% of patients, respectively, still receiving treatment.

ORIC compared those results with estimated 10-month rates of 63% and 54% for mevrometostat combined with enzalutamide in corresponding patient populations. Its cited estimates for approved therapies ranged from approximately 35% to 50% after abiraterone and 15% to 50% after an androgen-receptor inhibitor.

Fatigue, diarrhea and nausea were the most common treatment-related adverse events, reported in 32%, 24% and 22% of patients. None of the adverse events attributed to either combination drug were classified as Grade 4 or 5.

Lung-Cancer Trial Planned For 2027

Enozertinib, ORIC's brain-penetrant lung-cancer candidate, produced confirmed tumor responses in 84% of patients overall and 70% for brain tumors by investigators' assessments, as presented in October at ESMO Congress 2026. Independent blinded reviewers recorded rates of 80% and 67%, respectively. Longer-term response and progression data were still immature.

ORIC expects Redwood-1, its global late-stage enozertinib trial, to begin in the first half of 2027. The planned study would enroll approximately 360 patients with certain EGFR mutations, including patients with untreated brain metastases, and compare enozertinib with osimertinib or afatinib.

President and CEO Jacob M. Chacko said the company is "laser focused on execution" with late-stage studies underway or planned for both programs.

Another program, ORIC-259, will enter early clinical development through an agreement with Cancer Research UK. The organization will fund and run the development work; ORIC retains an option to regain rights after early- and mid-stage data, with milestone payments and royalties potentially payable to Cancer Research UK.

ORIC also plans enozertinib data in mid-2027 covering treatment alone and combinations with amivantamab or chemotherapy. Those updates and the planned Redwood-1 start are the next milestones within its projected funding window.

Sources

More on Oric Pharmaceuticals

All Oric Pharmaceuticals (ORIC) coverage →